We also utilized the submap algorithm to compare the similarity of the expression profiles between the three TIME phenotypes and 47 previous melanoma patients with detailed immunotherapeutic information, and revealed that patients in TIME-3 were more responsive to anti-PD1 treatment (Bonferroni corrected P = 0.008)[30] (Fig. 3h). This evidence concerns the gene PDCD1 and melanoma.